ABSTRACT OBJECTIVES This study sought to evaluate acute and long-term outcomes of percutaneous paravalvular regurgitation (PVR) closure after transcatheter aortic valve replacement (TAVR).
T ranscatheter aortic valve replacement (TAVR) is an effective treatment for patients with severe symptomatic aortic stenosis who are considered either ineligible or at high risk for surgical AVR (1,2). After conventional AVR, the occurrence of paravalvular regurgitation (PVR) is infrequent and often necessitates rapid action (3,4). Conversely, residual PVR is more common after TAVR and has been reported in up to 90% of the patients independent of either of the 2 available types of devices and approaches (5) . In most cases, PVR is mild and clinically silent. However, when moderate or severe it has been associated with hemodynamic deterioration and worse early (6) and late (7) clinical outcome.
When aortic regurgitation (AR) is exclusively or mainly paravalvular, the possible mechanisms are as follow: 1) malposition (too high or too low with respect to the aortic annulus); 2) annulus/prosthesis mismatch; 3) incomplete expansion of the prosthesis stent frame; and 4) presence of bulky calcified nodules preventing the good adherence of the bioprosthesis to the left ventricular outflow tract. Based on the pathophysiology, the management strategy includes post-dilation (8) , valve-in-valve implantation (9) , or repositioning with the snare technique (10) . Sometimes, however, none of these techniques are effective, necessitating additional maneuvers.
Transcatheter closure of PVR has been previously described for post-surgical valves (11, 12) . More recently, percutaneous device closure of PVR following TAVR have been described in small series, with single center experience and have focused on a particular valve type (13) (14) (15) (16) (17) . In addition, the devices In terms of efficacy, PVR grade was significantly reduced in most of the patients (Figure 2) , and these results seemed durable. The mortality rate at follow-up was high, but in most of the cases, deaths were due to noncardiac causes and related to the severe comorbidities. The high rate of mortality, however, may still raise concerns. We did not have a reliable control population, so it is difficult to estimate the true impact of our procedures on the final outcome. Previous studies reported 1-year mortality rates between 30% and 70% in patients with moderate-to-severe AR after TAVR (24) (25) (26) (27) (28) (29) . Considering available data and the fact that 87.5% of our patients were deemed inoperable, in many instances because of comorbidity other than that captured by surgical scores, the fatality rate of our series seems more justifiable. the valve-in-valve technique (9) . This procedure is very effective, has a favorable procedural outcome, and should probably be preferred when severe AR is manifest at the end of TAVR procedure. Our study suggests that transcatheter PVR closure may be considered as an alternative to a second TAVR procedure when valve-in-valve is not performed during the first procedure, as long as there is a focal area where a device can be of use. High implantation of the prosthetic valve was a less frequent event in our series, maybe because it is less amenable to transcatheter treatment described herein. Post-dilation maybe helpful in these cases; however, valve-invalve is the best treatment, especially for high implants with risk of embolization. The second prosthesis should preferably be a balloon-expandable valve, because it is required to be implanted in a lower position, whereas with the self-expandable prosthesis, the outflow tract may remain underexpanded into the first prosthesis.
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Closure of Paravalvular Regurgitation After TAVR
Another relevant mechanism of PVR after TAVR is annulus/prosthesis mismatch, that is, implantation of an undersized prosthesis in relation to the aortic annulus (30) . Preventing incongruence between the aortic annulus and the device is of paramount importance; hence, multimodality assessment of the aortic annulus size is recommended before TAVR.
Previous studies provided the evidence for a more reliable measurement of aortic annulus and less PVR by using 3-dimensional cross-section computed tomography-scan assessment (31) . Post-dilation may be attempted in these cases, and only if there is a focal residual PVR should a closure device could be considered.
STUDY LIMITATIONS. This is a small, retrospective study and the use of closure devices for treatment of PVR was off-label, driven by the clinical necessity.
The lack of a comparison group makes it difficult to estimate the benefit of the procedure beyond the impact on AR severity and reported changes in functional status. Larger experience will be needed to confirm safety and efficacy of this procedure. New sizing strategies, which include multimodality imaging of the aortic annulus and computed tomography measurement of annular diameters, perimeter, and area will likely help decrease the incidence of severe PVR. Next-generation valves have been designed to address the limitations of the first-generation devices, including features to reduce PVR such as sealing skirts or cuffs and the ability to reposition. This may change the incidence, the need, and the technique to close PVR (32, 33) . 
CONCLUSIONS
